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Abstract
To test the hypothesis that use of oral contraceptives (OC) changes diurnal vari-
ation in fluid balance mechanisms including blood pressure, secretion of vaso-
pressin and oxytocin, and renal water and electrolyte excretion. Fifteen naturally
cycling (NC) women in mid-follicular phase and 11 long-term OC users were
included in a 24-h standardized inpatient study for measurements of vaso-
pressin, oxytocin, sodium, and osmolality in plasma as well as urinary excretion
of electrolytes, aquaporin-2, and prostaglandin E2. Blood pressure and heart rate
were monitored noninvasively. Plasma vasopressin showed circadian rhythm
(P = 0.02) and were similar in both groups (P = 0.18) including nighttime
increases (P < 0.001). There was no circadian rhythm in plasma oxytocin within
(P = 0.84) or between groups (P = 0.22). OC users had significantly lower
plasma osmolality (Dosm: 3.05  0.29 mosm/kg, P = 0.04) and lower plasma
sodium (DNa+: 0.91  0.09 mmol/l, P = 0.05). The two groups showed similar
nighttime decreases in diuresis (1.08  0.04 mL/(kgh), P < 0.001) and
increases in urine osmolality (109  9 mosm/kg, P = 0.02), but similar rates of
excretion of Aquaporin-2, prostaglandin E2 and sodium. Nighttime decreases in
mean arterial pressure of approximately 13% were significant in both groups
(P < 0.001), but 24-h average mean arterial pressure was significantly higher in
OC users than in controls (+4.7  0.4 mmHg, P = 0.02). Packed cell volumes
were similar between groups (P = 0.54). OC does not change the diurnal pat-
terns of renal fluid excretion, but resets the osmoreceptors for vasopressin
release and leads to a significant increase in arterial blood pressure.
Introduction
The influence of oral contraceptives on blood pressure
and fluid balance is not fully elucidated and several
homeostatic mechanisms are potentially involved.
Studies in young women have found that estrogens reset
the osmoreceptors for thirst and AVP release during high
estrogen phases (the luteal phase/oral contraceptives (OC))
(Stachenfeld et al. 1999; Calzone et al. 2001). Yet another
study has shown that the well-established nighttime
increase in vasopressin (AVP) was attenuated in pre-
menopausal women taking OC (Kostoglou-Athanassiou
et al. 1998). In postmenopausal women, steroid ovarian
hormones influence secretion of both oxytocin and AVP.
Estrogen was found to increase AVP concentration,
whereas progesterone suppressed the vasopressin concen-
tration (Bossmar et al. 1995). Previously, we have been
focusing on the impact of estrogen on the renal regulation
of urine production. Eight women were investigated both
in the follicular and the luteal phase of the menstrual cycle.
There was a preserved nocturnal increase in AVP with both
low and high levels of estrogen and no difference in the
concentration of AVP, diuresis, urine osmolality, and
excretion of aquaporin 2 (AQP2) (Graugaard-Jensen et al.
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2008). However, this could be due to possibility that the
minor difference in estrogen between the two phases of the
normal menstrual cycle was too subtle to reveal an effect.
Exogenous oxytocin is clearly antidiuretic and can
cause water intoxication if administered to pregnant
women during delivery (Rasmussen et al. 2004; Wang
et al. 2000). The affinity of oxytocin to the V2 receptor
is, however, much lower than that of vasopressin (Joo
et al. 2004). Whether oxytocin possesses an antidiuretic
effect under normal physiological conditions is not fully
elucidated. Only a few studies have examined the diurnal
rhythm of oxytocin, and the results are inconclusive, con-
cerning the influence on urine production (Kostoglou-
Athanassiou et al. 1998; Forsling et al. 1998; Landgraf
et al. 1982). High estrogen levels, as present in OC users,
have been found to increase the concentration of oxytocin
(Kostoglou-Athanassiou et al. 1998; Amico et al. 1981;
Mitchell et al. 1981) but whether this is sufficient to
induce antidiuresis is still unknown.
The role of urinary prostaglandin E2 (PGE2) in renal
water handling is still unclear. The urinary excretion of
PGE2 is thought to reflect renal prostaglandin production
with an effect on both sodium channels (Ando and Asano
1995) renal hemodynamics, and AVP-regulated water
reabsorption (Anderson et al. 1975; Berl et al. 1977).
Excess nocturnal PGE2 excretion is seen in patients with
nocturnal polyuria provoked by sleep-deprivation (Mahler
et al. 2012; Haack et al. 2009) and in desmopressin-resis-
tant nocturnal polyuria in children (Kamperis et al.
2012). In rats, estrogen affects the biosynthesis of PGE2
in the kidney (Chang 1989). Whether estrogen affects the
renal PGE2 production in women is uncertain. Several
studies have found that urinary PGE2 excretion was stable
during the normal menstrual cycle (Stachenfeld et al.
2003; Stratton et al. 1986), whereas others have shown
that the urinary excretion of PGE-2 is elevated by ovarian
stimulation (Moutquin et al. 1984). The latter could indi-
cate that PGE-2 may modulate the diurnal urine regula-
tion in women taking OC’s.
This study was designed to investigate, whether the
enhanced estrogen concentrations obtained with OC use
(third generation) affect the diurnal regulation of urine
production with focus on the relationship between
AVP, oxytocin, AQP2, and PGE2. Women in midfollic-
ular phase were compared to women taking oral con-
traceptives. We hypothesized that oral contraceptives
decrease the concentration of AVP, attenuate the noc-
turnal increase in AVP, and increase the concentration
of oxytocin, which subsequently will modulate the out-
come of urine production. In addition, we assessed
whether it was possible to compare the in-patient study
design to everyday life using the volunteer’s home
recordings.
Materials and Methods
The regional Committee on Biomedical Research Ethics
approved this study protocol, and informed consent was
obtained from all participants.
Study subjects
Fifteen healthy nonsmoking natural cycling women (NC)
and 11 healthy nonsmoking long-term OC (3. generation
with 20 lg estradiol and gestoden/desogestrel) users were
recruited by advertisement at the University of Aarhus.
Part of the data obtained from the 15 young women has
previously been published (Graugaard-Jensen et al. 2008;
Graugaard-Jensen C et al. 2014). Inclusion criteria were
age 20–35 years, BMI < 30, a normal physical examina-
tion including blood pressure measurements and for the
women without OC use, a regular menstrual cycle (26–
33 days). Participants had normal plasma-creatinine,
sodium, potassium, hemoglobin, and a normal urine
analysis. A complete bladder emptying upon voiding was
determined by postvoid ultrasound estimation. There
were no reports of nocturia or any other urological com-
plaints, no previous surgery, no history of severe illnesses,
or use of any medication except for the oral contracep-
tives.
Study design
The experimental procedure consisted of a 24-h in-patient
study under standardized conditions regarding sodium
and water intake. The natural cycling women were inves-
tigated in midfollicular phase (7–10 days after their last
period began), and the women who used OC were inves-
tigated during the pill-period. A 3-day frequency/volume
chart (FVC) was obtained from all participants. Time and
volume (mL) of each micturition and of each fluid intake
were recorded. Intake of fluid and food were ad libitum,
and the subjects were asked not to alter their habits dur-
ing the home recordings. The time of rising and the bed-
time were noted.
Two days prior to the admission, the participants were
fluid preconditioned to 30 mL/kg body weight 24/h. The
participants were told to refrain from alcohol and caf-
feinated beverages and heavy physical activities 24 h before
the admission. The participants were admitted at 7 AM. An
intravenous access was established in a cubital vein of the
nondominant arm. During the experimental period, diet
and fluid intake were standardized as directed by a clinical
dietitian (sodium 3 mmol/kg body weight 24/h and 30 mL
tap water kg1 body weight 24/h distributed equally during
the day, 2/5 before 12:00, 2/5 from 12:00 to 18:00 and 1/5
from 18:00 until bedtime). Meals were served at 8:00,
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12:00, and 18:00 h. Activity was allowed from arrival until
23:00. Sleep during daytime was not allowed. The OC was
taken just before bedtime. From 23:00 the participants had
to be in supine position. Physical activity, food, and fluid
intake during the night were not allowed.
Blood samples were drawn every 6 h until 20:00,
thereafter every 3 h. The Participants were seated in a
chair 30 min before blood sampling during the day
(8:00–23:00 h). During the night (23:00–08:00 h) sam-
ples were taken in the supine position. Care was taken
not to wake up the participants during blood sampling
at night. The blood samples were replaced by isotonic
saline. Blood samples were transported on ice, cen-
trifuged at +4°C. They were stored at 80°C unless
immediately analyzed. Blood samples were analyzed for
AVP, creatinine, osmolality, and sodium. Estradiol, pro-
gesterone, and testosterone were measured only once
(day 1, 08:00 h).
Urine was collected with 3-h intervals following sponta-
neous voiding. Participants were asked to empty their
bladder just after blood sampling during the day, before
bedtime and upon wakening in the morning. All other
voiding was free at will. Nocturnal urine was collected in
a bottle during the night and the participants were asked
to empty their bladder in the same bottle at 08:00, day 2.
Urine volume and the concentration of creatinine, osmo-
lality, and sodium were measured. Aliquots were stored at
80°C for analysis of PGE2 and AQP2.
Blood pressure and heart rate (HR) was monitored by
cuff every hour with an automatic ambulatory blood
pressure monitor (ABP Monitor 90207 TM SpaceLabs
Medical, Inc, Redmond, WA).
Blood and urine analysis
Plasma and urine concentration of sodium, creatinine,
estradiol, and testosterone were measured using routine
procedures at the department of Clinical Biochemistry.
Plasma and urine osmolality were measured using the
freezing point depression method (AdvancedTM Osmome-
ter model 3900, Advanced Instruments, Norwood, MA).
AVP was determined in plasma by radioimmunoassay
(RIA) (Bie and Sandgaard 2000) using a highly specific
AVP antibody (AB3096) as previously described (Emme-
luth et al. 1994). AVP was extracted from plasma using
Sep-Pak  Plus C18 extraction cartridges (Waters Corpo-
ration, Milford, MA). The detection limit was 0.10 pg/mL
plasma and the intra and interassay coefficients of varia-
tion were 7.7% and 10.6%, respectively.
Oxytocin was measured in plasma following extraction
on Sep-Pak  Plus C18 extraction cartridge by RIA using
an oxytocin-specific rabbit-antibody kindly provided by
Dr. M. Morris, Dayton, OH. The detection level was
0.9 pg/mL; inter and intraassay coefficients of variation
were 11.0% and 7.5%, respectively.
A commercial enzyme immunoassay kit (Amersham
Pharmacia Biotech, Little Chalfont, UK) was used to deter-
mine the PGE2 concentration in the urine without prior
extraction. Interassay and intraassay were approximately
13% and 9%. The detection limit was 40 pg/mL.
AQP2 was measured directly in urine using radioim-
munoassay (RIA). A modification of a previous described
method was used (Saito et al. 1997; Pedersen et al. 2001).
Detection limit was 16 pg/mL urine. The PGE2 and
AQP2 measurements were performed at the Water and
Salt Research Center, Aarhus University Hospital, Den-
mark.
Calculations
On the basis of urine and plasma measurements, excre-
tion rates (E) and clearances (C) were calculated for
sodium, creatinine, osmoles, PGE2, and APQ2 using stan-
dard formulas. Solute-free water reabsorption (TC H2O)
is the difference between osmolar clearance (Cosmol) and
urine flow (Uflow). The clearance of creatinine was used
as an estimate of glomerular filtration rate.
Statistical analyses
To compensate for the variability in body weight in the
study population urinary excretion rates are expressed per
kg body weight. The results are presented as
mean  SEM. To compare the variation over time for
the two groups, we used a mixed effect ANOVA with a
subject specific random effect using time and group as
fixed effects, as well as their interaction, if this was statis-
tically significant (Wald’s test). When quantifying the
day-night differences, we created an indicator variable
(day at time points 8:00, 14:00, 20:00, and 23:00 and
night at time points 2:00, 5:00, and 8:00), and used this
variable in place of time in the mixed effect model. When
appropriate, the data were log-transformed to fit the sta-
tistical model. These data are presented as geometric
mean with normal 95% confidence intervals. Home
recordings were compared to the in-patient study using
Student‘s t tests. Correlations were calculated using Pear-
son0s correlation. Nondetectable values were set to equal
half the detection level. Results were considered signifi-
cant at P < 0.05.
Results
Table 1 shows the demographic data of the participants.
There was no difference in age or BMI between the two
groups.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Hormones and plasma values
Plasma sodium, osmolality, and creatinine all displayed a
significant diurnal variation (P < 0.001). OC users
showed significantly lower plasma osmolality (Dosm
3.05  0.29 mosm/kg, P = 0.04) and plasma sodium
(DNa+: 0.92  0.09 mmol/L, P = 0.05) than the natural
cycling women (Fig. 1). Packed cell volume was similar
between the groups (P = 0.54). Clearance of creatinine
was calculated as an estimate of GFR and corrected for
body weight; the values were similar (P = 0.38) and
showed no day to night variation (P = 0.19).
There was no significant difference in P-AVP between
the groups (P = 0.18), but both groups had a significant
nighttime increase (P = 0.02). For AVP, nocturnal
increases of approximately 34% (95%-CI: 15–56%) were
found for both groups (P < 0.001). P-oxytocin did not
differ between the groups (P = 0.22) or over time
(P = 0.83) (Fig. 2). The concentration of endogenous
progesterone (day 1, 0800 h) was higher in the natural
cycling women than in OC users (3.15  0.25 nmol/L vs.
1.99  0.15 nmol/L, P < 0.001). There was no difference
in testosterone between the groups (1.55  0.11 vs.
1.24  0.12 nmol/L, P = 0.07). Endogenous estrogen was
higher in the natural cycling women (0.30  0.04 vs.
0.09  0.01 nmol/L, P < 0.001).
Diuresis
Diuresis and urine osmolality showed diurnal rhythms.
Diuresis peaked in late afternoon (OC users) or evening
(NC) and showed minima at night. The observed night-
time reductions in urine production were highly signifi-
cant (P < 0.001) and remarkably similar in the two
groups (NC women: daytime: 1.90  0.15 mL/(kgh),
night: 0.86  0.07 mL/(kgh) and OC users daytime:
1.94  0.12 mL/(kgh), night: 0.80  0.10 mL/(kgh). A
diurnal rhythm in urine osmolality was found in both
groups (P < 0.001), but there was no difference between
groups (P = 0.60). Focusing on the day-to-night varia-
tion; urine osmolality increased significantly in the OC
group (daytime: 473  32 mosm/kg, night: 616  55
mosm/kg, P = 0.03). In the NC group, the nighttime
increase did not quite reach statistical significance (day-
time: 465  24 mosm/kg, night: 550  38 mosm/kg,
P = 0.07). Excretion of sodium displayed diurnal varia-
tion (P < 0.001) as well, and were similar in both groups
(P = 0.21). There was no difference in the excretion of
Table 1. Demographic data of the participants.
Participants BMI (kg/m2) Age (years)
Women with OC 11 24.3  0.7
Range (21.4–27.0)
23.6  2.3
Range (21–28)
Natural cycling women (NC) 15 22.7  0.6
Range (18.7–27.9)
25.5  2.8
Range (23–33)
Values are mean  SEM.
Figure 1. P-sodium and p-osmolality in women who uses OC (black triangles) and in the natural cycling women in midfollicular phase (white
circles). Values are mean  SEM.
2017 | Vol. 5 | Iss. 23 | e13547
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AQP2 (P = 0.56) or PGE2 (P = 0.73) between the groups.
Both had diurnal variation (P < 0.001), but only PGE2
displayed lower nighttime excretion (P < 0.001). (Fig. 3).
We found a significant positive correlation between AQP-
2 and urine osmolality (r = 0.4525, P < 0.001) and
reabsorption of free water (r = 0.44, P < 0.001), but no
correlation between AQP-2 excretion and secretion of
AVP. There was a negative correlation between 24 h
diuresis and AVP (r = 0.25, P < 0.005). A similar corre-
lation with oxytocin was not seen.
Hemodynamics
MAP was significantly higher in the women using oral con-
traceptives (OC: +4.7  0.4 mmHg, P = 0.02). The night-
time dip in MAP was evident and similar in both groups
(night: 10.3  0.2 mmHg, P < 0.001) (Fig. 4). The diur-
nal variation in heart rate (HR) showed lowest values at
night (Night: 7.9  0.1 bpm, P < 0.001). We found no
difference in HR between the groups (P = 0.19).
Home recordings
The 24 h fluid-intakes at home were similar in the two
groups (30.9  2.0 and 29.3  2.3 mL/kg body weight in
NC and OC women, respectively). The fluid intake at
home did not differ from the fluid intake in the inpatient
studies (NC women: P = 0.60, OC: P = 0.70). Twenty-
four-hour urine volume during the in-patient study was
significantly higher than in the home recordings in both
women and in OC users (P < 0.05). The day to night
ratios were, however, similar (NC women: inpatient:
4.1  0.5 vs. home: 3.9  0.4, P = 0.7, OC: in-patient:
4.8  0.8 vs. home: 3.2  0.4, P = 0.08).
Discussion
In this study, we have been investigating whether the
enhanced sex-hormone concentrations obtained with OC
use affect the diurnal regulation of urine production with
focus on the relationship between AVP, oxytocin, AQP2,
and PGE2.
Our study demonstrates that OC do not significantly
change the overall concentration or the circadian profile
of AVP, but confirms that high estrogen decreases both
plasma sodium and plasma osmolality reflecting the reset-
ting of the osmoreceptor for AVP release. There is no
diurnal rhythm in oxytocin, which does not seem to be
involved in renal regulation of fluid under normal physi-
ological conditions. A significantly higher blood pressure
was seen in the OC users. The urinary excretion of
sodium, AQP2, and PGE2 were similar in the two groups.
We were not able to show a statistically significant dif-
ference in baseline AVP values, but did find a preserved
nighttime increase in both groups. Baseline AVP levels
have been reported to be unchanged (Stachenfeld et al.
1999; Calzone et al. 2001) or decreased (Bossmar et al.
1995) in women taking OCs. Previously, it seems that
only one group has focused on diurnal investigations.
They demonstrated an attenuated nighttime increase in
AVP in women taking OCs (Kostoglou-Athanassiou et al.
1998). The discrepancy between the studies may be due
to different types and concentrations of estrogen and pro-
gesterone in the OCs used and probably the length of
treatment as well. The participants in our study were all
long-term (>1 year) users.
The resetting of the osmoreceptor function to a lower
osmotic threshold for AVP release is a well-known phe-
nomenon and occurs when estrogen is high (Stachenfeld
Figure 2. Diurnal rhythm of oxytocin and AVP in natural (white circles) and suppressed cycles (black triangles). Values are mean  SEM.
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Figure 3. Diurnal rhythm of urine osmolality, diuresis, and excretion rates of PGE-2 and AQP-2 in women without intake of OC (white circles)
or in OC users (black triangles). Bars are mean  SEM.
Figure 4. Mean arterial blood pressure (MAP) and heart rate (HR) in young women with natural (white circles) and suppressed cycles (black
triangles). Values are mean  SEM.
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et al. 1999; Calzone et al. 2001). This is confirmed in our
study. We found no difference in urine production or
urine osmolality between groups and can conclude that
the production of urine is unaffected by this resetting, as
indicated by other studies as well (Stachenfeld et al. 2003)
The influence of oxytocin on diuresis has been investi-
gated in both humans and animals. Evidence supports an
antidiuretic effect of oxytocin (Rasmussen et al. 2004; Joo
et al. 2004). In rats it has been documented that oxytocin
can function as an antidiuretic hormone at physiological
plasma levels (Chou et al. 1995). Infusion of oxytocin in
healthy young males led to a rise in plasma oxytocin to
50 pg/mL and resulted in an antidiuretic effect, which was
mediated by the vasopressin receptor, albeit with a much
lower affinity (Joo et al. 2004). Another previous study has
demonstrated an increase in p-oxytocin in women taking
OC (Kostoglou-Athanassiou et al. 1998) but whether this
administration would increase plasma oxytocin to a level
where it would exert antidiuresis remains undocumented.
We did not observe diurnal variation in the concentration
of oxytocin, nor did we show any difference between the
groups. Plasma levels stayed low, between 2 and 4 pg/mL
and there were no correlations to urine production. In
summary, oxytocin does not play a role in diurnal urine
formation under normal physiologic conditions, and intake
of OC will not increase the plasma concentration to levels
inducing an antidiuresis.
AVP and oxytocin exert their antidiuretic effect
through a binding to the V2 receptor in the principal cells
in the collecting ducts, thereby inserting AQP-2 water
channels, of which some subsequently will be excreted in
the urine (Nielsen et al. 1993; Wen et al. 1999; Rai et al.
1997). Under normal physiological conditions we would
anticipate elevated excretions of AQP-2 under maximal
antidiuresis during the night (Al-Dameh et al. 2003). The
lack of a nighttime increase in AQP-2 excretion in this
study may be due to the study design. We focused on the
diurnal rhythm of hormones regulating the urine produc-
tion. Healthy volunteers do not normally have nocturnal
micturition and the increase in AQP-2 excretion follow-
ing the nocturnal rise in AVP would easily be blurred due
to overnight sampling. Elucidation of the true circadian
profile under normal physiologic conditions would
require a urethral catheter and subsequent analysis of the
hourly excretion of AQP-2 during the night. However,
the associated discomfort may disrupt the sleep and thus
adversely affect the diurnal rhythm.
Urinary excretion of PGE-2 revealed a distinct diurnal
rhythm in excretion, but these were similar in the two
groups. Gonadotropin-induced ovulation with a subse-
quent increase in estradiol will lead to elevation of the
urinary PGE-2 excretion (Moutquin et al. 1984). This has
led some authors to suggest that a p-estradiol above
normal range will result in increased PGE-2 excretion
(Stachenfeld et al. 2003). But what if estrogen is com-
bined with progesterone as in oral contraceptives? In a
study in postmenopausal women, estrogen and proges-
terone in combination, decreased the excretion of PGE2
(Akgul et al. 1998). Our participants used OC’s and the
content of both estrogen and progesterone can be the rea-
son for the rejection of our hypothesis and it is from our
study not possible to make any definite conclusions.
Mean arterial blood pressure was slightly, but signifi-
cantly increased in the women taking oral contraceptives.
Differences in body weight cannot explain the difference
as the women had similar BMI. A mild rise in blood pres-
sure is well-known in connection with ingestion of oral
contraceptives (Oelkers et al. 1995) even though it was
more marked using the old formulations with higher con-
tent of estrogen (Boldo and White 2011). Causes of BP
increase in women taking oral contraceptives are multiple
and complex, but activation of the renin–angiotensin sys-
tem (RAS) is involved (Boldo and White 2011). Ingestion
of oral contraceptives with a high level of estrogen will
result in an increased sympathetic tone and subsequently
in a higher blood pressure (Minson et al. 2000; Carter
et al. 2009). Progesterone is a mineralocorticoid antago-
nist and has marked natriuretic effect. The synthetic pro-
gesterone in the oral contraceptives are devoid of the
antimineralocorticoid effect and cannot counteract the
sodium retaining properties of estrogen (Oelkers 1996).
As a consequence, OC may promote sodium and water
retention and subsequently increase blood pressure.
We were not able to demonstrate a decrease in sodium
excretion in the OC group compared to non-OC users.
However, the participants were in steady state with regard
to sodium handling and as the experimental setup is
observational, we would not expect to see any difference.
Former studies, in which low-dose oral contraceptives
were used to elucidate the fluid balance, have shown a
significantly decreased sodium excretion when estrogen
was high (Stachenfeld et al. 1999; Calzone et al. 2001).
One explanation of this finding may be that these studies
are characterized by short-term use of oral contraceptives
(often only one cycle) and use the volunteers as their
own controls.
To ensure that the in-patient setup was comparable to
the participant’s everyday life a home study was con-
ducted. Observational studies are influenced by the sur-
roundings. Participants are admitted to the hospital for
24 hours, an intravenous cannula is inserted in their fore-
arm and blood samples are taken throughout the day and
night. This may change the sleep pattern and thereby the
diurnal water handling. The fluid intake was similar at
home and during the admission. The urine production
was higher during the in-patient investigation, but the
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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day to night ratios were similar. Despite this reservation
concerning the investigational circumstances, we found
that the inpatient setup can be used to describe the every-
day diurnal rhythm in urine formation.
The aim of this study was to describe the diurnal
rhythm in female renal water handling under influence of
oral contraceptives. Focus has been on AVP, oxytocin,
AQP2, and PGE2. OC resets the osmoreceptors for AVP
release and increases the blood pressure, whereas all other
variables were similar between the groups, and it seems as
if oral contraceptives do not alter the diurnal urine regu-
lation.
However, this design has some limitations. All partici-
pants were preconditioned with fluid before admission,
but we have not controlled for food (sodium) intake at
home. They were asked to refrain from hard physical
activity the last 2 days prior to admission, but we actually
do not know if all have followed these rules, and the sub-
jects could be either dehydrated or overhydrated as they
arrived at the hospital. During the hospital stay, however,
they were assigned to strict rules concerning fluid and
foodintake.
Furthermore, the hormones in the follicular phase are
not at all stable and the progestins in the OC have some
androgenic properties compared to the endogenous pro-
gesterone. As the investigation has been done some years
ago, all participants were at that time treated with oral
contraceptives from the third generation containing 20 lg
ethinylestradiol and either gestodene (7) or desogestrel
(4). The fact that we used two different progestins could
have an impact on the results. However, both are highly
potent with a low androgenic activity and serum levels
and pharmacokinetics of the two substances are compara-
ble (Stanczyk 1997). Due to the modest number of partic-
ipants, it is not possible to subdivide the groups. This
means that it is not possible to discuss the isolated effect
of high estrogen, but only the overall effect of third gen-
eration of OCs on diurnal urine production. To elucidate
an independent effect of estrogen are highly warranted.
This will, however, require a completely different design.
Acknowledgments
The authors thank Claus Dethlefsen for the invaluable
statistical advice and help performing the statistical analy-
sis. The authors also thank Jane Knudsen, Bodil Kris-
tensen, Gitte Kall, and Gitte Skou for their expert
technical assistance.
Conflicts of Interest
No conflicts of interest, financial or otherwise, are
declared by any of the authors.
References
Akgul, C., M. Canbaz, P. Vural, A. Yildirim, and N. Geren.
1998. Hormone replacement therapy and urinary
prostaglandins in postmenopausal women. Maturitas 30:79–
83.
Al-Dameh, A., J. J. Bedford, J. P. Leader, and R. J. Walker.
2003. Urinary aquaporin-2 levels in healthy volunteers.
Nephrology 8:139–141.
Amico, J. A., S. M. Seif, and A. G. Robinson. 1981. Elevation
of oxytocin and the oxytocin-associated neurophysin in the
plasma of normal women during midcycle. J. Clin.
Endocrinol. Metab. 53:1229–1232.
Anderson, R. J., T. Berl, K. D. McDonald, and R. W. Schrier.
1975. Evidence for an in vivo antagonism between
vasopressin and prostaglandin in the mammalian kidney. J.
Clin. Invest. 56:420–426.
Ando, Y., and Y. Asano. 1995. Luminal prostaglandin E2
modulates sodium and water transport in rabbit cortical
collecting ducts. Am. J. Physiol. 268:F1093–F1101.
Berl, T., A. Raz, H. Wald, J. Horowitz, and W. Czaczkes. 1977.
Prostaglandin synthesis inhibition and the action of
vasopressin: studies in man and rat. Am. J. Physiol. 232:
F529–F537.
Bie, P., and N. C. Sandgaard. 2000. Determinants of the
natriuresis after acute, slow sodium loading in conscious dogs.
Am. J. Physiol. Regul. Integr. Comp. Physiol. 278:R1–R10.
Boldo, A, and W. B. White. 2011. Blood pressure effects of the
oral contraceptive and postmenopausal hormone therapies.
Endocrinol. Metab. Clin. North Am. 40: 419–432ix.
Bossmar, T., M. Forsling, and M. Akerlund. 1995. Circulating
oxytocin and vasopressin is influenced by ovarian steroid
replacement in women. Acta Obstet. Gynecol. Scand.
74:544–548.
Calzone, W. L., C. Silva, D. L. Keefe, and N. S. Stachenfeld.
2001. Progesterone does not alter osmotic regulation of
AVP. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281:
R2011–R2020.
Carter, J. R., J. E. Lawrence, and J. C. Klein. 2009. Menstrual
cycle alters sympathetic neural responses to orthostatic stress
in young, eumenorrheic women. Am. J. Physiol. Endocrinol.
Metab. 297:E85–E91.
Chang, W. C. 1989. Effects of estradiol on prostaglandin E2
biosynthesis and prostaglandin metabolic enzyme activity in
rat kidneys. Adv. Prostaglandin Thromboxane Leukot. Res.
19:225–228.
Chou, C. L., S. R. DiGiovanni, R. Mejia, S. Nielsen, and M. A.
Knepper. 1995. Oxytocin as an antidiuretic hormone. I.
Concentration dependence of action. Am. J. Physiol. 269:
F70–F77.
Emmeluth, C., C. Drummer, R. Gerzer, and P. Bie. 1994.
Natriuresis in conscious dogs caused by increased carotid
[Na+] during angiotensin II and aldosterone blockade. Acta
Physiol. Scand. 151:403–411.
2017 | Vol. 5 | Iss. 23 | e13547
Page 8
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society
A Diurnal Study In Young Women C. G.-Jensen et al.
Forsling, M. L., H. Montgomery, D. Halpin, R. J. Windle, and
D. F. Treacher. 1998. Daily patterns of secretion of
neurohypophysial hormones in man: effect of age. Exp.
Physiol. 83:409–418.
Graugaard-Jensen C, G. M. Hvistendahl, J. Frokiaer, P. Bie,
and J. C. Djurhuus. 2014.Urinary concentration does not
exclusively rely on plasma vasopressin. A study between
genders. Gender and diurnal urine regulation. Acta Physiol.
(Oxf) 212: 97–105.
Graugaard-Jensen, C., G. M. Hvistendahl, J. Frokiaer, P. Bie,
and J. C. Djurhuus. 2008. The influence of high and low
levels of estrogen on diurnal urine regulation in young
women. BMC Urol. 8:16.
Haack, M., E. Lee, D. A. Cohen, and J. M. Mullington. 2009.
Activation of the prostaglandin system in response to sleep
loss in healthy humans: potential mediator of increased
spontaneous pain. Pain 145:136–141.
Joo, K. W., U. S. Jeon, G. H. Kim, J. Park, Y. K. Oh, Y. S.
Kim, et al. 2004. Antidiuretic action of oxytocin is
associated with increased urinary excretion of aquaporin-2.
Nephrol. Dial. Transplant. 19:2480–2486.
Kamperis, K., S. Rittig, W. F. Bower, and J. C. Djurhuus.
2012. Effect of indomethacin on desmopressin resistant
nocturnal polyuria and nocturnal enuresis. J. Urol.
188:1915–1922.
Kostoglou-Athanassiou, I., P. Athanassiou, D. F. Treacher, M.
J. Wheeler, and M. L. Forsling. 1998. Neurohypophysial
hormone and melatonin secretion over the natural and
suppressed menstrual cycle in premenopausal women. Clin.
Endocrinol. (Oxf) 49:209–216.
Landgraf, R., R. Hacker, and H. Buhl. 1982. Plasma
vasopressin and oxytocin in response to exercise and during
a day-night cycle in man. Endokrinologie 79:281–291.
Mahler, B., K. Kamperis, M. Schroeder, J. Frokiaer, J. C.
Djurhuus, and S. Rittig. 2012. Sleep deprivation induces
excess diuresis and natriuresis in healthy children. Am. J.
Physiol. Renal Physiol. 302:F236–F243.
Minson, C. T., J. R. Halliwill, T. M. Young, and M. J. Joyner.
2000. Sympathetic activity and baroreflex sensitivity in
young women taking oral contraceptives. Circulation
102:1473–1476.
Mitchell, M. D., P. J. Haynes, A. B. Anderson, and A. C.
Turnbull. 1981. Plasma oxytocin concentrations during the
menstrual cycle. Eur. J. Obstet. Gynecol. Reprod. Biol.
12:195–200.
Moutquin, J. M., H. Wyman, J. Van Campenhout, and J.
Lord. 1984. The concentrations of urinary prostaglandins E
and plasma prostaglandins F2 alpha and E during induction
of ovulation with human gonadotropins. Prostaglandins
Leukot. Med. 13:197–209.
Nielsen, S., S. R. DiGiovanni, E. I. Christensen, M. A.
Knepper, and H. W. Harris. 1993. Cellular and subcellular
immunolocalization of vasopressin-regulated water channel
in rat kidney. Proc. Natl Acad. Sci. USA 90:11663–11667.
Oelkers, W. K. 1996. Effects of estrogens and progestogens on
the renin-aldosterone system and blood pressure. Steroids
61:166–171.
Oelkers, W., J. M. Foidart, N. Dombrovicz, A. Welter, and R.
Heithecker. 1995. Effects of a new oral contraceptive
containing an antimineralocorticoid progestogen,
drospirenone, on the renin-aldosterone system, body weight,
blood pressure, glucose tolerance, and lipid metabolism. J.
Clin. Endocrinol. Metab. 80:1816–1821.
Pedersen, R. S., H. Bentzen, J. N. Bech, and E. B. Pedersen.
2001. Effect of water deprivation and hypertonic saline
infusion on urinary AQP2 excretion in healthy humans.
Am. J. Physiol. Renal Physiol. 280:F860–F867.
Rai, T., K. Sekine, K. Kanno, K. Hata, M. Miura, A.
Mizushima, et al. 1997. Urinary excretion of aquaporin-2
water channel protein in human and rat. J. Am. Soc.
Nephrol. 8:1357–1362.
Rasmussen, M. S., J. A. Simonsen, N. C. Sandgaard, P. F.
Hoilund-Carlsen, and P. Bie. 2004. Effects of oxytocin in
normal man during low and high sodium diets. Acta
Physiol. Scand. 181:247–257.
Saito, T., S. E. Ishikawa, S. Sasaki, T. Nakamura, K. Rokkaku,
A. Kawakami, et al. 1997. Urinary excretion of aquaporin-2
in the diagnosis of central diabetes insipidus. J. Clin.
Endocrinol. Metab. 82:1823–1827.
Stachenfeld, N. S., C. Silva, D. L. Keefe, C. A. Kokoszka, and
E. R. Nadel. 1999. Effects of oral contraceptives on body
fluid regulation. J. Appl. Physiol. 1985 87:1016–1025.
Stachenfeld, N. S., H. S. Taylor, C. A. Leone, and D. L. Keefe.
2003. Oestrogen effects on urine concentrating response in
young women. J. Physiol. 552:869–880.
Stanczyk, F. Z. 1997. Pharmacokinetics of the new
progestogens and influence of gestodene and
desogestrel on ethinylestradiol metabolism. Contraception
55:273–282.
Stratton, J. A., R. D. Miller, D. R. Kent, P. S. Weathersbee, L.
D. Thrupp, C. A. Richards, et al. 1986. Effect of oral
contraceptives on leukocyte phagocytic activity and plasma
levels of prostaglandin E2 and thromboxane B2 in normal
menstruating women. Am. J. Reprod. Immunol. Microbiol.
10:47–52.
Wang, J. Y., S. H. Lin, Y. F. Lin, H. Y. Chen, F. C. Yu, and M.
T. Fu. 2000. An unforgotten cause of acute hyponatremia:
water intoxication due to oxytocin administration in a
pregnant woman. Nephron 86:342–343.
Wen, H., J. Frokiaer, T. H. Kwon, and S. Nielsen. 1999.
Urinary excretion of aquaporin-2 in rat is mediated by a
vasopressin-dependent apical pathway. J. Am. Soc. Nephrol.
10:1416–1429.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society
2017 | Vol. 5 | Iss. 23 | e13547
Page 9
C. G.-Jensen et al. A Diurnal Study In Young Women
